Enanta's NASH drug barely meets main goal in mid-stage study
A platoon of drug developers big and small has long been working on combating NASH, a fatty liver disease that has ravaged the developed world. On Wednesday, Enanta Pharmaceuticals unveiled data from a short mid-stage study which suggested its liver drug had — by a minuscule margin — met the main goal in NASH patients.
The drug, EDP-305, is a Farnesoid X Receptor (FXR) agonist, akin to Intercept’s $ICPT obeticholic acid, which produced mixed data in a landmark phase III study. FXR is a nuclear receptor and a crucial regulator of bile acid levels in the liver and small intestine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.